From GlobeNewswire: 2025-03-31 09:00:00

Connect Biopharma announced key leadership appointments, with Barry Quart, Pharm.D. as CEO and David Szekeres as President. The company unveiled a rapid clinical development program for rademikibart targeting acute care in asthma and COPD. They expect to begin Phase 2 trials in 2Q 2025 with data expected in 2H 2026. The company has a strong balance sheet with cash runway into 2027.

Connect Biopharma reported financial results for the year ended December 31, 2024. Revenue totaled $26.0 million, with cash, cash equivalents, and short-term investments at $93.7 million. Operating expenses decreased, with a net loss of $15.6 million for 2024. The company expects its cash position to fund operations into 2027.

Connect Biopharma is a clinical-stage biopharmaceutical company focused on asthma and COPD. They are advancing rademikibart, an anti-IL-4Rα antibody. Rademikibart has shown efficacy in asthma trials, with rapid improvements in pulmonary function. The company’s goal is to address the unmet needs of asthma and COPD patients with acute exacerbations.



Read more at GlobeNewswire:: Connect Biopharma Reports 2024 Full-Year Financial Results